Kairos Pharma (NYSEAMERICAN:KAPA) Shares Down 0.1% – Time to Sell?

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) shares dropped 0.1% during trading on Friday . The stock traded as low as $0.6402 and last traded at $0.6644. Approximately 126,041 shares changed hands during mid-day trading, a decline of 31% from the average daily volume of 181,725 shares. The stock had previously closed at $0.6648.

Analyst Upgrades and Downgrades

Separately, D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Kairos Pharma in a research note on Wednesday, November 19th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $8.33.

Kairos Pharma Stock Performance

The stock has a market cap of $13.83 million, a price-to-earnings ratio of -2.14 and a beta of 2.28. The business’s 50 day moving average is $0.79 and its 200 day moving average is $1.02.

Kairos Pharma (NYSEAMERICAN:KAPA) last released its earnings results on Friday, November 14th. The company reported ($0.07) earnings per share for the quarter.

Institutional Trading of Kairos Pharma

Several large investors have recently made changes to their positions in the stock. Two Sigma Investments LP acquired a new stake in Kairos Pharma in the 3rd quarter valued at approximately $54,000. XTX Topco Ltd bought a new stake in shares of Kairos Pharma in the 2nd quarter worth approximately $44,000. Finally, FNY Investment Advisers LLC bought a new position in Kairos Pharma in the third quarter worth $27,000.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.